Publications by authors named "David L Becton"

Claim this Profile
I
Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital.
Pritmohinder S Gill, Feliciano B Yu, Patricia A Porter-Gill, Bobby L Boyanton, Judy C Allen, David L Becton

J Pers Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity.
Kimo C Stine, Elizabeth C Wahl, Lichu Liu, Robert A Skinner, Jaclyn VanderSchilden, David L Becton

J Orthop Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin inhibits bone healing during distraction osteogenesis.
Kimo C Stine, Elizabeth C Wahl, Lichu Liu, Robert A Skinner, Jacquelyn Vanderschilden, David L Becton

J Orthop Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bleeding disorders: when is normal bleeding not normal?
Kimo C Stine, David L Becton

J Ark Med Soc· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors.
Kimo C Stine, Dixie Shrum, David L Becton

J Pediatr Hematol Oncol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy.
Kimo C Stine, Robert L Saylors, C Suzanne Saccente, David L Becton

Clin Appl Thromb Hemost· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
Süreyya Savaşan, Steven Buck, Susana C Raimondi, David L Becton, Howard Weinstein

Leuk Lymphoma· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Yubin Ge, Alan A Dombkowski, Katherine M LaFiura, Dana Tatman, Ravikiran S Yedidi, David L Becton

Blood· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Childhood luekemia--success and challenges.
David L Becton

J Ark Med Soc· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
Norman J Lacayo, Soheil Meshinchi, Paivi Kinnunen, Ron Yu, Yan Wang, David L Becton

Blood· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis.
Kimo C Stine, Robert L Saylors, Suzanne Saccente, Kenneth L McClain, David L Becton

Pediatr Blood Cancer· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate.
Kimo C Stine, Robert L Saylors, Suzanne Saccente, David L Becton

Med Pediatr Oncol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
Wayne L Furman, Clinton F Stewart, Mark Kirstein, James L Kepner, Mark L Bernstein, David Lee Becton

J Clin Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis